• LAST PRICE
    1.2500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.2500/ 1
  • Ask / Lots
    1.2800/ 6
  • Open / Previous Close
    0.0000 / 1.2500
  • Day Range
    ---
  • 52 Week Range
    Low 0.6501
    High 2.1200
  • Volume
    100
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.08
TimeVolumeCLSD
09:32 ET124281.1799
09:34 ET21981.16
09:36 ET105141.1899
09:38 ET54001.175
09:39 ET2001.18
09:41 ET151991.16
09:43 ET63001.175
09:45 ET67831.165
09:48 ET20001.1401
09:50 ET60001.14
09:52 ET93941.14
09:54 ET2891.135
09:56 ET5001.14
09:57 ET13441.135
09:59 ET575591.1142
10:01 ET40201.0802
10:03 ET1421.1
10:06 ET4001.1098
10:12 ET52001.11
10:15 ET2001.14
10:28 ET5141.12
10:30 ET13001.125
10:35 ET63001.12
10:46 ET1001.12
10:48 ET71431.11
10:50 ET64581.125
10:51 ET8981.11
10:55 ET20001.125
10:57 ET2001.13
11:02 ET18001.1499
11:04 ET58001.15
11:15 ET66411.16
11:18 ET122591.165
11:20 ET40001.1564
11:22 ET2001.17
11:26 ET66001.19
11:27 ET1117081.23
11:29 ET76001.2112
11:31 ET148141.23
11:33 ET10231.2301
11:36 ET37001.25
11:38 ET14791.25
11:42 ET3971.2123
11:44 ET3001.22
11:45 ET15121.2299
11:47 ET109501.23
11:49 ET57501.2101
11:51 ET16141.23
11:54 ET2001.22
11:56 ET6001.22
12:00 ET132861.2343
12:02 ET95981.25
12:03 ET547701.27
12:05 ET41271.2799
12:07 ET27951.26
12:09 ET298321.24
12:12 ET5001.24
12:14 ET15721.255
12:16 ET10001.2599
12:18 ET31001.26
12:20 ET30001.2687
12:21 ET31911.265
12:27 ET31011.23
12:32 ET9541.2626
12:38 ET5001.2518
12:39 ET8501.25
12:41 ET57801.2599
12:43 ET1571.2565
12:45 ET15021.2424
12:48 ET218831.235
12:50 ET14001.235
12:52 ET4001.235
12:56 ET13671.25
12:57 ET30001.235
01:01 ET2001.2411
01:03 ET26251.27
01:06 ET32691.2646
01:08 ET127111.22
01:10 ET56001.2299
01:12 ET23291.2217
01:14 ET1001.2206
01:17 ET1001.2224
01:21 ET1001.225
01:24 ET12961.22
01:26 ET14441.25
01:28 ET11601.2274
01:32 ET100001.22
01:33 ET1001.25
01:42 ET2101.24
01:44 ET10001.22
01:55 ET10451.23
01:57 ET10941.22
02:00 ET7001.23
02:02 ET11001.24
02:04 ET4001.24
02:06 ET12131.25
02:11 ET1001.2426
02:26 ET3001.25
02:29 ET20001.2301
02:36 ET2001.24
02:38 ET1001.24
02:40 ET1001.24
02:44 ET208691.17
02:49 ET36001.2299
02:51 ET2001.215
02:56 ET1001.215
02:58 ET1001.215
03:02 ET10001.2004
03:03 ET31221.23
03:12 ET3001.215
03:16 ET5001.22
03:18 ET109801.24
03:20 ET16971.25
03:21 ET95001.2402
03:23 ET76921.25
03:25 ET15001.23
03:32 ET21121.25
03:38 ET29001.25
03:39 ET22471.24
03:41 ET18471.2401
03:43 ET55001.25
03:45 ET11001.25
03:48 ET29001.2401
03:50 ET14001.27
03:52 ET33221.2699
03:56 ET43221.27
03:57 ET16321.25
03:59 ET131041.25
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCLSD
Clearside Biomedical Inc
93.4M
-2.3x
---
United StatesAFMD
Affimed NV
87.1M
-0.9x
---
United StatesCOYA
Coya Therapeutics Inc
93.6M
-6.9x
---
United StatesIKNA
Ikena Oncology Inc
81.1M
-1.1x
---
United StatesARMP
Armata Pharmaceuticals Inc
100.5M
-1.3x
---
United StatesVXRT
Vaxart Inc
122.1M
-1.3x
---
As of 2024-06-26

Company Information

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Contact Information

Headquarters
900 North Point Parkway, Suite 200ALPHARETTA, GA, United States 30005
Phone
678-270-3631
Fax
678-270-4033

Executives

Independent Chairman of the Board
William Humphries
President, Chief Executive Officer, Director
George Lasezkay
Chief Financial Officer
Charles Deignan
Chief Medical Officer
Victor Chong
Director
Anthony Gibney

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$93.4M
Revenue (TTM)
$8.5M
Shares Outstanding
74.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.43
EPS
$-0.54
Book Value
$-0.25
P/E Ratio
-2.3x
Price/Sales (TTM)
11.1
Price/Cash Flow (TTM)
---
Operating Margin
-282.45%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.